Qiagen (OTCMKTS: NVZMY) and NOVOZYMES A/S/S (OTCMKTS:NVZMY) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership and analyst recommendations.
NOVOZYMES A/S/S pays an annual dividend of $0.49 per share and has a dividend yield of 0.9%. Qiagen does not pay a dividend. NOVOZYMES A/S/S pays out 30.8% of its earnings in the form of a dividend.
Institutional & Insider Ownership
65.2% of Qiagen shares are owned by institutional investors. Comparatively, 0.2% of NOVOZYMES A/S/S shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This table compares Qiagen and NOVOZYMES A/S/S’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings and price targets for Qiagen and NOVOZYMES A/S/S, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Qiagen currently has a consensus price target of $39.60, indicating a potential upside of 3.91%. NOVOZYMES A/S/S has a consensus price target of $54.97, indicating a potential upside of 2.18%. Given Qiagen’s stronger consensus rating and higher possible upside, equities analysts plainly believe Qiagen is more favorable than NOVOZYMES A/S/S.
Risk & Volatility
Qiagen has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, NOVOZYMES A/S/S has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500.
Valuation & Earnings
This table compares Qiagen and NOVOZYMES A/S/S’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Qiagen||$1.42 billion||6.14||$40.39 million||$1.27||30.01|
|NOVOZYMES A/S/S||$2.21 billion||5.93||$473.62 million||$1.59||33.83|
NOVOZYMES A/S/S has higher revenue and earnings than Qiagen. Qiagen is trading at a lower price-to-earnings ratio than NOVOZYMES A/S/S, indicating that it is currently the more affordable of the two stocks.
Qiagen Company Profile
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions. It also provides Ingenuity Variant Analysis, a cloud-based platform that interprets data from next-generation sequencing (NGS) analysis; QIAGEN Clinical Insight, an evidence-based decision support solution; CLC Genomics Workbench for the analysis and visualization of data from various NGS platforms; and GeneGlobe, a Web-based portal that enables researchers to search and select gene-and pathway-specific solutions from pre-designed and custom PCR assay kits, NGS assay panels, and other products. In addition, the company offers instrumentation systems for laboratories. Its automation platforms include QIAsymphony, a modular system; GeneReader NGS System, a sample to insight NGS solution for laboratories to deliver actionable results; QIAcube robotic workstations, which provides versatile solutions for automated sample processing; QIAxcel for nucleic acid separation; QIAgility, a benchtop instrument for PCR setup; and ESEQuant instruments that enable optical measurement for point of need molecular testing in physician practices, emergency rooms, remote areas, and other applications. It serves molecular diagnostics, applied testing, pharma, and academia customers. QIAGEN N.V. has a collaboration with Bristol-Myers Squibb to develop gene expression profiles for immuno-oncology therapies. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
NOVOZYMES A/S/S Company Profile
Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide. It operates in three divisions: Household Care & Technical, Agriculture & Bioenergy, and Food & Beverages. The company offers enzymes for use in household care products, such as laundry detergents, hand and automatic dishwashing soaps, and professional cleaning products. It also provides enzymes for baking applications, including freshness, product appearance, dough improvement, etc.; and brewing applications comprising fermentation control, separation and filtration, etc., as well as for use in lactose-free dairy, trans fats removal, etc. in the food and beverages industry. In addition, the company offers enzymes and microorganisms for use in the production of cellulosic ethanol, starch-based ethanol, enzymatic biodiesel, and sugarcane ethanol in the bioenergy industry; and feed enzymes for use in animal feed, probiotics for animal health applications, microbials for aquaculture applications, and other enzymes and microorganisms for plant health and crop yield applications in the agriculture and feed industry. Further, it provides enzymes and microorganisms for use in textile processing, pulp and paper production, leather preparation, pharmaceuticals, and wastewater treatment solutions. The company has a strategic collaboration with Boehringer Ingelheim Animal Health for research and development, production, marketing, and sale of a portfolio of probiotic products. Novozymes A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.